Focus: Charter Medical is a specialty pharmaceutical company based in Winston-Salem, NC focused on single-use devices across neurology, cardiovascular, oncology, infectious diseases, and metabolic disease indications. The company generates meaningful revenue from a concentrated portfolio of branded and generic products.
Profile data last refreshed 5h ago · AI intelligence enriched 2mo ago
Stable — net +1 jobs in 30d
3 added, 2 removed. Backfill posture.
Charter Medical offers a stable niche position in specialty pharmaceuticals, but the lack of pipeline innovation, extreme revenue concentration, and zero active hiring make it suitable only for candidates seeking mature-company operational roles with minimal growth upside.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Anchor product driving 71% of company revenue; approaching loss of exclusivity creates major revenue cliff risk.
Help build intelligence for Charter Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Charter Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Small revenue contributor nearing patent expiration in mid-2030; minimal financial impact but represents only identified future cliff.
Generic product post-loss of exclusivity; modest revenue contributor with limited growth potential.
Very small revenue contributor in post-LOE stage with minimal market presence.
Generic calcium channel antagonist with multiple formulations; commodity-level competitive environment.
63 discontinued, 50 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
+34 more products
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo